<p align=center>Email sended at 07-08-2017 08:37:14</p>
              	<li>to:</li>
                <li>headers:From: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
BCC: g.contino@cineca.it
CC: sclafanin@aou-careggi.toscana.it
Reply-To: <>
Return-Path: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
Message-ID: <1502095034-comitati-etici-toscana@no-reply.it>
MIME-Version: 1.0
Content-Type: multipart/mixed;
 boundary="3239c08b31895e26ed98a48c616c6825"

</li>
                <li>oggetto:Segreteria CEAV Centro - notifica di parere sospensivo</li>
                <li>testo:La segreteria CEAV Centro ha inviato parere sospensivo per lo studio 'Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to determine the Efficacy and Safety of Vedolizumab in Prevention ofEndoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis : REPREVIO(recurrence prevention with Entyvio)'.<br> E' possibile visualizzarne i dettagli tramite il seguente link:<br> <a href="https://ricercaclinica-toscana.cineca.it/uxmr/index.php?&exams=visite_exam.xml&ID_STUD=10577">Vai allo studio</a>&nbsp;</li>
                <hr>